{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:49:20Z","timestamp":1761518960509},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,3,21]],"date-time":"2010-03-21T00:00:00Z","timestamp":1269129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Surrogate markers of HIV disease progression are HIV RNA in plasma viral load (VL) and CD4 cell count (immune function). Despite improved international access to antiretrovirals, surrogate marker diagnostics are not routinely available in resource\u2010limited settings. Therefore, the objective was to assess effects of economic and diagnostic resourcing on patient treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Analyses were based on 2333 patients initiating highly active antiretroviral therapy (HAART) from 2000 onwards. Sites were categorized by World Bank country income criteria (high\/low) and annual frequency of VL (\u22653, 1\u20132 or &lt;1) or CD4 (\u22653 or &lt;3) testing. Endpoints were time to AIDS\/death and change in CD4 cell count and VL suppression (&lt;400 HIV\u20101 RNA copies\/mL) at 12 months. Demographics, Centers for Disease Control and Prevention (CDC) classification, baseline VL\/CD4 cell counts, hepatitis B\/C coinfections and HAART regimen were covariates. Time to AIDS\/death was analysed by proportional hazards models. CD4 and VL endpoints were analysed using linear and logistic regression, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Increased disease progression was associated with site\u2010reported VL testing less than once per year [hazard ratio (HR)=1.4; <jats:italic>P<\/jats:italic>=0.032], severely symptomatic HIV infection (HR=1.4; <jats:italic>P<\/jats:italic>=0.003) and hepatitis C virus coinfection (HR=1.8; <jats:italic>P<\/jats:italic>=0.011). A total of 1120 patients (48.2%) had change in CD4 cell count data. Smaller increases were associated with older age (<jats:italic>P<\/jats:italic>&lt;0.001) and \u2018Other\u2019 HIV source exposures, including injecting drug use and blood products (<jats:italic>P<\/jats:italic>=0.043). A total of 785 patients (33.7%) contributed to the VL suppression analyses. Patients from sites with VL testing less than once per year [odds ratio (OR)=0.30; <jats:italic>P<\/jats:italic>&lt;0.001] and reporting \u2018Other\u2019 HIV exposures experienced reduced suppression (OR=0.28; <jats:italic>P<\/jats:italic>&lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Low measures of site resourcing were associated with less favourable patient outcomes, including a 35% increase in disease progression in patients from sites with VL testing less than once per year.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2010.00822.x","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T04:00:16Z","timestamp":1269230416000},"page":"519-529","source":"Crossref","is-referenced-by-count":24,"title":["Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD)"],"prefix":"10.1111","volume":"11","author":[{"given":"R","family":"Oyomopito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MP","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Phanuphak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PL","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Ditangco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YMA","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Pujari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sungkanuparph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CKC","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kamarulzaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FJ","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CV","family":"Mean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Merati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Tau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PCK","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of The TREAT Asia HIV Observational Database","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,4]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030264"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030265"},{"key":"e_1_2_7_4_2","unstructured":"UNAIDS.AIDS epidemic update: special report on HIV\/AIDS 2006. Available athttp:\/\/www.unaids.org\/en\/KnowledgeCentre\/HIVData\/EpiUpdate\/EpiUpdArchive\/2006\/default.asp."},{"key":"e_1_2_7_5_2","first-page":"509","article-title":"Antiretroviral therapy in resource\u2010poor settings","volume":"34","author":"Egger M","year":"2005","journal-title":"scaling up inequalities?"},{"key":"e_1_2_7_6_2","first-page":"174","article-title":"The TREAT Asia HIV Observational Database","volume":"38","author":"Zhou J","year":"2005","journal-title":"baseline and retrospective data"},{"key":"e_1_2_7_7_2","first-page":"262","article-title":"Implementation of an antiretroviral access program for HIV\u20101\u2010infected individuals in resource\u2010limited settings","volume":"44","author":"Sow PS","year":"2007","journal-title":"clinical results from 4 African countries"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(02)00264-7"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-12-199706150-00003"},{"key":"e_1_2_7_10_2","first-page":"827","article-title":"Treatment for adult HIV infection","volume":"296","author":"Hammer SM","year":"2006","journal-title":"2006 recommendations of the International AIDS Society \u2013 USA panel"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-12-199706150-00001"},{"key":"e_1_2_7_12_2","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents. Department of Health and Human Services.2008:1\u2013128. Available athttp:\/\/www.aidsinfo.nih.gov(accessed 21 April 2008)."},{"key":"e_1_2_7_13_2","unstructured":"European AIDS Clinical Society (EACS).Guidelines for the clinical management and treatment of HIV infected adults in Europe. Available athttp:\/\/www.europeanaidsclinicalsociety.org(accessed 21 April 2008)."},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000279710.47298.5c"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441108"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa060247"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030417"},{"key":"e_1_2_7_18_2","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"CDC.","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_7_19_2","unstructured":"World Bank.World Bank list of economies. Available athttp:\/\/go.worldbank.org\/K2CKM78CC0(accessed July 2007)."},{"key":"e_1_2_7_20_2","first-page":"119","article-title":"Prognosis of HIV\u20101\u2010infected patients starting highly active antiretroviral therapy","volume":"360","author":"Egger M","year":"2002","journal-title":"a collaborative analysis of prospective studies"},{"key":"e_1_2_7_21_2","first-page":"817","article-title":"Mortality of HIV\u20101\u2010infected patients in the first year of antiretroviral therapy","volume":"367","author":"Braitstein P","year":"2006","journal-title":"comparison between low-income and high-income countries"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/498908"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200307010-00011"},{"key":"e_1_2_7_24_2","first-page":"1800","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV\u20101 and hepatitis C virus coinfection","volume":"356","author":"Greub G","year":"2000","journal-title":"the Swiss HIV Cohort Study"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31802c7e20"},{"key":"e_1_2_7_26_2","first-page":"407","article-title":"Normalisation of CD4 counts in patients with HIV\u20101 infection and maximum virological suppression who are taking combination antiretroviral therapy","volume":"370","author":"Mocroft A","year":"2007","journal-title":"an observational cohort study"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309260-00002"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922201750461285"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-59"},{"key":"e_1_2_7_30_2","first-page":"223","article-title":"Immune restoration with antiretroviral therapies","volume":"284","author":"Lederman MM","year":"2000","journal-title":"implications for clinical management"},{"key":"e_1_2_7_31_2","unstructured":"United Nations General Assembly.Declaration of Commitment on HIV\/AIDS and Political Declaration on HIV\/AIDS: midway to the Millennium Development Goals 2008. Available athttp:\/\/www.un.org\/ga\/president\/62\/issues\/hiv\/A\u201062\u2010780.pdf(accessed 18 May 2008)."},{"key":"e_1_2_7_32_2","first-page":"1443","article-title":"Outcomes from monitoring of patients on antiretroviral therapy in resource\u2010limited settings with viral load, CD4 cell count, or clinical observation alone","volume":"371","author":"Phillips AN","year":"2008","journal-title":"a computer simulation model"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280141fdf"},{"key":"e_1_2_7_34_2","first-page":"306","article-title":"High frequency of clinically significant mutations after first\u2010line generic highly active antiretroviral therapy failure","volume":"49","author":"Kumarasamy N","year":"2009","journal-title":"implications for second-line options in resource-limited settings"},{"key":"e_1_2_7_35_2","unstructured":"World Health Organisation.Towards universal access: scaling up priority HIV\/AIDS interventions in the health sector 2008. Available athttp:\/\/www.who.int\/hiv\/pub\/towards_universal_access_report_2008.pdf(accessed 2 July 2008)."},{"key":"e_1_2_7_36_2","unstructured":"World Health Organisation.Technical Working Group for the development of an HIV\/AIDS diagnostic support toolkit 2002. Available athttp:\/\/www.who.int\/bct(accessed 23 January 2009)."},{"issue":"2","key":"e_1_2_7_37_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801302S03","article-title":"The World Health Organization's global strategy for prevention and assessment of HIV drug resistance","volume":"13","author":"Bennett DE","year":"2008","journal-title":"Antivir Ther"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2010.00822.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2010.00822.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:37:13Z","timestamp":1698640633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2010.00822.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,4]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1468-1293.2010.00822.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00822.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2010,8,4]]}}}